Richard Gold, Conscience’s Chief Policy and Partnerships Officer, has co-authored an editorial in Science with Robert Cook-Deegan calling for global coordination and public investment in high-quality, open datasets to enable AI-driven drug discovery. Drawing lessons from past successes like the Protein Data Bank and the Human Genome Project, the authors argue that the future of AI in medicine depends on open, standardized data managed by trusted, independent organizations. Without this foundation, the promise of AI to reduce drug development costs and address urgent health needs—especially in data-scarce areas—will remain out of reach.
